Wissam Fayad, MD
Geriatric Medicine · Yuma, AZNPI 1902841810
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,154 of the $1,283 with a category attached, or 89.9%. It is spread thinly across 28 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $323 and has fallen 67.0% since, to $106 in 2025.
Across 59 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$260
- Astellas Pharma US Inc$210
- Novo Nordisk$103
- AstraZeneca$102
- Mylan Specialty L.p.$69
- AbbVie$67
- plus $471 from 22 others
What the payments were for
- Food & beverage$1,15490%
- Education$12910%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 2 | $260 |
| Astellas Pharma US Inc | 10 | $210 |
| Novo Nordisk | 6 | $103 |
| AstraZeneca | 6 | $102 |
| Mylan Specialty L.p. | 4 | $69 |
| AbbVie(2 entities) | 3 | $67 |
| Eisai Inc. | 3 | $46 |
| Pfizer | 2 | $38 |
| Tactile Systems Technology Inc | 2 | $38 |
| UCB, Inc. | 1 | $31 |
| Medtronic | 1 | $30 |
| Philips North America LLC | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Abbott | 1 | $22 |
| GE HealthCare | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Boston Scientific | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $17 |
| GSK | 1 | $17 |
| Mannkind Corporation | 1 | $15 |
| Amgen | 1 | $14 |
| Novartis | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Bayer | 1 | $11 |
| Bioventus LLC | 1 | $11 |
How this compares
$1,283 in reported general payments places this provider in the 80th percentile of 75 geriatric medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 203 | $257,059 |
| EliquisApixaban | 164 | $216,761 |
| MounjaroTirzepatide | 62 | $75,042 |
| JardianceEmpagliflozin | 32 | $50,283 |
| MyrbetriqMirabegron | 41 | $49,137 |
| FarxigaDapagliflozin Propanediol | 49 | $42,633 |
| TrulicityDulaglutide | 26 | $40,139 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $33,144 |
| XareltoRivaroxaban | 26 | $30,652 |
| JanuviaSitagliptin Phosphate | 26 | $27,613 |
| TradjentaLinagliptin | 21 | $24,625 |
| LinzessLinaclotide | 25 | $20,298 |
| Humulin R U-500Insulin Regular, Human | 14 | $20,042 |
| EntrestoSacubitril/Valsartan | 16 | $18,648 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $15,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $103 | $257,059203 claims |
| PfizerEliquis | $38 | $216,761164 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $102 | $75,77793 claims |
| Astellas Pharma US IncMyrbetriq | $210 | $49,13741 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $17 | $25,34935 claims |
| AbbVieLinzess | $67 | $20,29825 claims |
| NovartisEntresto | $13 | $18,64816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 75 geriatric medicine providers in Arizona.
Other geriatric medicine in Yuma
- John MiglianoTucson$100K
- Robin MacdougallPhoenix$51K
- John HomanTucson$18K
- Raghav MohindraPrescott Valley$16K
- Albert RuttingerSurprise$11K
- Rikesh DesaiSurprise$8K
- Aureliano CifuentesTempe$8K
- Ramakrishnan SubbureddiarTucson$7K
- Anil NandaPhoenix$4K
- Scott BernsteinScottsdale$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.